


Journal Pre-proof

Standardized multi-vendor compositional MRI of knee cartilage: a key step towards clinical translation?

James W. MacKay, Frank W. Roemer, Feliks Kogan



PII: S1063-4584(20)31117-1

DOI: <https://doi.org/10.1016/j.joca.2020.08.007>

Reference: YJOCA 4710

To appear in: *Osteoarthritis and Cartilage*

Received Date: 14 August 2020

Accepted Date: 18 August 2020

Please cite this article as: MacKay JW, Roemer FW, Kogan F, Standardized multi-vendor compositional MRI of knee cartilage: a key step towards clinical translation?, *Osteoarthritis and Cartilage*, <https://doi.org/10.1016/j.joca.2020.08.007>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Title

Standardized multi-vendor compositional MRI of knee cartilage: a key step towards clinical translation?

Authors

James W MacKay^{1,2}, Frank W Roemer^{3,4}, Feliks Kogan⁵

¹Norwich Medical School, University of East Anglia, Norwich, UK

²Department of Radiology, University of Cambridge, Cambridge, UK

³Department of Radiology, Friedrich-Alexander University Erlangen-Nürnberg & Universitätsklinikum Erlangen, Erlangen, Germany

⁴Quantitative Imaging Center, Department of Radiology, Boston University School of Medicine, Boston, MA

⁵Department of Radiology, Stanford University, Stanford CA

Corresponding author

Dr James MacKay

Bob Champion Research and Education Building

Norwich Medical School

University of East Anglia

Norwich NR4 7UQ

United Kingdom

James.w.mackay@uea.ac.uk

+44 788 2459094

1 Cartilage compositional magnetic resonance imaging (MRI) techniques are sensitive to changes
2 in the composition of the extracellular matrix of articular cartilage. Their promise lies in the
3 potential to detect the earliest stages of cartilage degeneration, at a stage where these changes
4 may still be reversible. This is a considerable advantage over conventional (structural) MRI;
5 even with the high spatial-resolution imaging offered by modern high-field (3T) MRI systems, by
6 the time structural cartilage damage is apparent, there is (by definition) damage to the collagen
7 matrix implying that the changes are probably already irreversible¹.

8
9 A wide variety of cartilage compositional MRI techniques have been described over the past
10 three decades (Table 1). The most widely used of these is T_2 (transversal relaxation time)
11 mapping, which is now available as a product (i.e., commercially available) pulse sequence from
12 all three major MRI vendors (GE, Siemens and Phillips). $T_{1\rho}$ (longitudinal relaxation time in the
13 presence of a radiofrequency field) mapping is an alternative which may offer improved
14 dynamic range to T_2 mapping but is not widely available (typically requiring a research
15 agreement to be in place with the MRI vendor). Both T_2 and $T_{1\rho}$ have considerable advantages
16 over other cartilage compositional techniques making them the most amenable to widespread
17 use. They do not require the administration of contrast agent, unlike delayed gadolinium
18 enhanced MRI of cartilage (dGEMRIC), do not require specialist hardware, unlike sodium
19 imaging, and are feasible at clinically accessible field strengths (i.e., 1.5 or 3 Tesla), unlike
20 sodium imaging and glycosaminoglycan chemical exchange saturation transfer (gagCEST). The
21 trade-off is that T_2 and $T_{1\rho}$ do not have the same tissue specificity as some of these other
22 techniques, for example dGEMRIC has a stronger correlation with proteoglycan content than

1 does $T_{1\rho}$ ². However, when performed correctly, they have been shown to be able to distinguish
2 between patients with or at risk of OA from healthy controls and predict development and
3 progression of OA (Figure 1)³⁻⁵. They may also offer considerably improved sensitivity to change
4 when compared to structural MRI or plain radiography^{6,7}.

5

6 [FIGURE 1]

7 [TABLE 1]

8

9 Despite the clear promise of T_2 and $T_{1\rho}$ mapping, both technical and clinical issues have
10 hindered the widespread uptake of these techniques. Both techniques were introduced more
11 than 20 years ago but there have been several obstacles to clinical use and acceptance by the
12 community. From a technical point of view, there is a lack of standardization of acquisition
13 protocols across different sites and vendors, with a wide variety of sequences available which
14 may or may not be commercially available. It is therefore little surprise that multi-vendor
15 reproducibility has previously been reported as suboptimal⁸. Linked to this, in many previous
16 studies there has been wide variance in selection of sequence parameters and a lack of
17 understanding of the effect of signal-to-noise ratio (SNR) on data quality. This has led to poorly
18 executed studies and thus inconclusive or difficult to interpret results. From a clinical point of
19 view, there is no established threshold for what constitutes a normal vs abnormal value of T_2
20 or $T_{1\rho}$ – nor is there likely to be, given the well-characterized variation between healthy
21 individuals and within the same individual across different cartilage subregions. Although
22 efforts have been made to standardize cross-sectional assessment using healthy reference

1 cohorts and Z-scores, in our opinion the real clinical utility of these methods is likely to be the
2 assessment of change within an individual over time and particularly in monitoring the earliest
3 disease stages that are likely to be the ones most amenable to non-surgical therapy^{9,10}.
4 Ultimately, clinical utility is also limited by the lack of demonstrable effect on patient
5 management, although there may be exceptions to this (e.g. suitability for and follow-up of
6 focal cartilage repair treatments such as autologous chondrocyte implantation) and this is a
7 limitation applicable to all advanced imaging of OA.

8
9 The article in the present issue by Kim and colleagues¹⁴ represents an important step in
10 addressing the suboptimal multi-site reproducibility of T_2 and $T_{1\rho}$ mapping. The key innovation
11 is the implementation of the same pulse sequence structure (3D magnetization-prepared angle-
12 modulated partitioned k-space spoiled gradient echo snapshots, or MAPSS) across all three
13 major MRI vendor platforms. This vendor-neutrality is a significant advance over previous multi-
14 site standardization efforts which have used vendor-specific pulse sequences (Table 2). They
15 demonstrate excellent intra-site repeatability for both T_2 and $T_{1\rho}$, in agreement with previous
16 studies and confirming the ability of these methods to detect relatively small longitudinal
17 changes in this setting: Inter-site reproducibility was not as good (as would be expected), but as
18 mentioned above the utility of these methods is likely to be for the detection of longitudinal
19 changes. Therefore, intra-site repeatability is of most interest, assuming an individual is imaged
20 on the same platform at baseline and follow-up visits. As alluded to above, interpretability of
21 many existent studies using T_2 and $T_{1\rho}$ is limited by the lack of acquisition and analysis expertise.
22 In particular, the quality of data used to generate the T_2 and $T_{1\rho}$ maps is often hampered by low

1 SNR and suboptimal parameter selection. The contribution of this study in providing a
2 reproducible set of parameters suitable to generate images of sufficient quality for valid
3 cartilage T_2 and $T_{1\rho}$ quantification across all major MRI vendor platforms is therefore to be
4 welcomed. An important extension of the current work would be an evaluation of inter-site and
5 inter-vendor variability of longitudinal changes in T_2 and $T_{1\rho}$.

6
7 [TABLE 2]

8
9 This work builds on existing efforts by the authors and others to develop T_2 and $T_{1\rho}$ as
10 quantitative imaging biomarkers suitable for use in clinical trials and clinical practice. It provides
11 further evidence of the excellent intra-site repeatability of these methods and highlights the
12 challenges associated with multi-site and multi-vendor implementation. The Quantitative
13 Imaging Biomarkers Alliance (QIBA), an initiative endorsed by the Radiologic Society of North
14 America (RSNA) with the aim to foster collaboration to identify needs, barriers and solutions to
15 create consistent, reliable, valid and achievable quantitative imaging results across imaging
16 platforms, clinical sites, and timepoints, recently published a statement regarding the
17 application of compositional MRI in degenerative joint disease
18 (https://qibawiki.rsna.org/images/2/20/QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf). QIBA
19 aims to promote quantitative imaging in clinical trials and clinical practice, with profile
20 statements to improve method standardization. As part of this, options for accessing the 3D
21 MAPSS pulse sequence used in this study are provided for all three major MRI vendors. The

1 profile is open for public comment through 29 September 2020 and we would encourage any
2 interested party to review and contribute.

3

4 What does all this mean for the general OA researcher? First, there are ongoing international
5 efforts to improve the accessibility and utility of T_2 and $T_{1\rho}$ to non-imaging specialist
6 researchers. This involves work both on standardization of image acquisition (exemplified by
7 the work of Kim and colleagues in this issue) but also on standardization of image analysis. The
8 latter often involves automated approaches built on AI algorithms which should reduce time
9 burden taken for analysis (particularly segmentation), improve integration into clinical
10 workflow and reduce variability associated with the use of different analysis pipelines^{11,12}.
11 Second, the pathway to routine clinical use of T_2 and $T_{1\rho}$ for cartilage assessment in OA cannot
12 be followed by the imaging community alone; technical validation and improvement in data
13 quality must be accompanied by clinical validation (demonstration of how is patient care
14 influenced, for example assisting clinicians in assessing response to therapy) and demonstration
15 of cost effectiveness in order to achieve clinical translation¹³. Therefore, in order for the
16 potential of these powerful techniques to be realized, it will be important to have support from
17 the wider OA research community.

18

1 Author contributions

- 2 1. All authors were involved in the conception and design of this editorial.
 - 3 2. All authors contributed to drafting the article or revising it critically for important
4 intellectual content.
 - 5 3. All authors gave their final approval of the manuscript to be submitted.
- 6 Responsibility for the integrity of the work as a whole is taken by James MacKay, MB BChir PhD
7 (first author; james.w.mackay@uea.ac.uk).

8 Competing interests

- 9 JM, FK have no competing interests.
- 10 FWR is Chief Medical Officer and shareholder of Boston Imaging Core Lab (BICL), LLC a company
11 providing image assessment services.

12 Funding and role of the funding source

13 No funding was received for this study.

14

1 References

- 2 1. Heinemeier KM, Schjerling P, Heinemeier J, et al. Radiocarbon dating reveals minimal
3 collagen turnover in both healthy and osteoarthritic human cartilage. *Sci Transl Med*.
4 2016;8(346):346ra90–346ra90.
- 5 2. van Tiel J, Kotek G, Reijman M, et al. Is T1 ρ Mapping an Alternative to Delayed
6 Gadolinium-enhanced MR Imaging of Cartilage in the Assessment of Sulphated
7 Glycosaminoglycan Content in Human Osteoarthritic Knees? An in Vivo Validation Study.
8 *Radiology*. 2016;279(2):523-531. doi:10.1148/radiol.2015150693
- 9 3. MacKay JW, Low SBL, Smith TO, Toms AP, McCaskie AW, Gilbert FJ. Systematic review and
10 meta-analysis of the reliability and discriminative validity of cartilage compositional MRI in
11 knee osteoarthritis. *Osteoarthritis Cartilage*. 2018;26(9):1140-1152.
12 doi:10.1016/j.joca.2017.11.018
- 13 4. Kretzschmar M, Nevitt MC, Schwaiger BJ, Joseph GB, McCulloch CE, Link TM. Spatial
14 distribution and temporal progression of T2 relaxation time values in knee cartilage prior
15 to the onset of cartilage lesions – data from the Osteoarthritis Initiative (OAI).
16 *Osteoarthritis Cartilage*. 2019;27(5):737-745. doi:10.1016/j.joca.2018.10.016
- 17 5. Prasad AP, Nardo L, Schooler J, Joseph GB, Link TM. T1 ρ and T2 relaxation times predict
18 progression of knee osteoarthritis. *Osteoarthritis Cartilage*. 2013;21(1):69-76.
19 doi:10.1016/j.joca.2012.09.011
- 20 6. Li X, Kuo D, Theologis A, et al. Cartilage in anterior cruciate ligament-reconstructed knees:
21 MR imaging T1 ρ and T2--initial experience with 1-year follow-up. *Radiology*.

- 1 2011;258(2):505-514. doi:10.1148/radiol.10101006
- 2 7. Monu UD, Jordan CD, Samuelson BL, Hargreaves BA, Gold GE, McWalter EJ. Cluster
3 analysis of quantitative MRI T2 and T1 ρ relaxation times of cartilage identifies differences
4 between healthy and ACL-injured individuals at 3T. *Osteoarthritis Cartilage*.
5 2017;25(4):513-520. doi:10.1016/j.joca.2016.09.015
- 6 8. Balamoody S, Williams TG, Wolstenholme C, et al. Magnetic resonance transverse
7 relaxation time T2 of knee cartilage in osteoarthritis at 3-T: a cross-sectional multicentre,
8 multivendor reproducibility study. *Skeletal Radiol*. 2013;42(4):511-520.
9 doi:10.1007/s00256-012-1511-5
- 10 9. Joseph G., McCulloch C.E., Nevitt M.C., et al. A reference database of cartilage T2 values in
11 knees without cartilage degeneration, and differences in cartilage T2 by demographics:
12 Data from the osteoarthritis initiative. *Osteoarthritis and Cartilage*.
13 10. Joseph GB, McCulloch CE, Nevitt MC, et al. Medial femur T2 Z-scores predict the
14 probability of knee structural worsening over 4-8 years: Data from the osteoarthritis
15 initiative. *J Magn Reson Imaging*. 2017;46(4):1128-1136. doi:10.1002/jmri.25662
- 16 11. Desai A. *Deep Open-Source Musculoskeletal MRI Analysis Software: Ad12/DOSMA*.; 2019.
17 Accessed March 29, 2019. <https://github.com/ad12/DOSMA>
- 18 12. Pedoia V, Li X, Su F, Calixto N, Majumdar S. Fully automatic analysis of the knee articular
19 cartilage T1 ρ relaxation time using voxel-based relaxometry. *J Magn Reson Imaging*.
20 2016;43(4):970-980. doi:10.1002/jmri.25065
- 21 13. O'Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer
22 studies. *Nat Rev Clin Oncol*. 2017;14(3):169-186. doi:10.1038/nrclinonc.2016.162

- 1 14. Kim J, Mamoto K, Lartey R, et al. Multi-vendor multi-site T1ρ and T2 quantification of knee
2 cartilage. *Osteoarthritis Cartilage*. Published online July 30, 2020.
3 doi:10.1016/j.joca.2020.07.005

Journal Pre-proof

1 Figure legends

2 **Figure 1.** $T_{1\rho}$ mapping predicts onset of focal morphological cartilage lesions. $T_{1\rho}$ mapping
3 overlaid on morphological MRI (3D fat-suppressed spoiled gradient echo) of patient undergoing
4 arthroscopic meniscectomy, performed pre-procedure (A) and at 6 months (B) and 1 year (C)
5 follow-up. Note development of focal region of elevated $T_{1\rho}$ (single arrow) at 6 months which
6 develops into an area of more diffuse partial thickness loss (double arrows) at 1 year (1 year
7 image shown without overlaid $T_{1\rho}$ map for clarity).

8

Table 1. Overview of commonly used cartilage compositional MRI techniques

Technique	Cartilage component assessed	Pros	Cons
T ₂ mapping	Collagen orientation, collagen content, water content	Easily accessible Feasible at 3T	Commercially available pulse sequences not optimized for cartilage
T _{1ρ} mapping	Macromolecular content, water content	Improved dynamic range c.f. T ₂ Feasible at 3T	Not readily available Similar information to T ₂ at clinically feasible spin-lock frequencies
T ₂ * mapping	Collagen orientation, collagen content, water content	Potentially faster acquisition c.f. T ₂ Can be combined with UTE imaging to assess deepest layers of cartilage Feasible at 3T	Similar information to T ₂ mapping but less well-validated UTE requires specialist non-Cartesian pulse sequences
dGEMRIC	GAG	GAG specificity	Requires IV contrast administration Complicated scan protocol
Sodium	GAG	GAG specificity	Difficult at < 7T Requires multinuclear capability
gagCEST	GAG	GAG specificity	Currently not feasible at < 7T
DWI/DTI	Proteoglycan content, collagen orientation	Combined proteoglycan/collagen assessment	Typically limited spatial resolution & SNR with standard DWI sequences

Abbreviations: UTE – ultrashort echo time, GAG – glycosaminoglycan, DWI – diffusion-weighted imaging, DTI – diffusion tensor imaging, SNR – signal-to-noise ratio.

Table 2. Comparison of standard T_2 and $T_{1\rho}$ MRI and MAPSS pulse sequence

Drawbacks of commercially available pulse sequence (i.e., spin echo-based)	Advantage conferred by MAPSS pulse sequence
Slow readout so TEs not optimized for cartilage, TE dependent on hardware considerations	Magnetization prepared so TE can be short, optimized for cartilage and standardized
First TE often has to be discarded due to stimulated echo effects	Stimulated echo not an issue as T2/T1 ρ magnetization preparation is utilized
Poor SNR efficiency, often 2D readout - so spatial resolution limited	3D readout with improved SNR efficiency
Multiple vendor-specific implementations	Single implementation available across multiple vendors

Abbreviations: SNR – signal-to-noise ratio, TE – echo time

